Functional screening of FGFR4-driven tumorigenesis identifies PI3K/mTOR inhibition as a therapeutic strategy in rhabdomyosarcoma.
McKinnon T, Venier R, Yohe M, Sindiri S, Gryder BE, Shern JF, Kabaroff L, Dickson B, Schleicher K, Chouinard-Pelletier G, Menezes S, Gupta A, Zhang X, Guha R, Ferrer M, Thomas CJ, Wei Y, Davani D, Guidos CJ, Khan J, Gladdy RA.
McKinnon T, et al. Among authors: schleicher k.
Oncogene. 2018 May;37(20):2630-2644. doi: 10.1038/s41388-017-0122-y. Epub 2018 Feb 28.
Oncogene. 2018.
PMID: 29487419
Free PMC article.